Lorlatinib-associated sensorineural deafness in a non-small cell lung cancer patient with ALK-fusion: a Case Report
Abstract
In the era of precision targeted therapy, anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) have significantly improved survival outcomes for patients with ALK-positive non-small cell lung cancer (NSCLC). The third-generation ALK inhibitor lorlatinib, characterized by superior antitumor activity, a broader spectrum of ALK mutation sites and enhanced central nervous system (CNS) penetrability, has yielded breakthrough clinical benefits. However, lorlatinib has a distinct adverse event profile, with edema, dyslipidemia, central and peripheral nervous system toxicities, posing key clinical management challenges. Herein, we report the first case of an ALK-fusion NSCLC patient who developed peripheral neuropathy, dysarthria, and sensorineural deafness following lorlatinib treatment. While dysarthria and peripheral neuropathy have been previously documented, sensorineural deafness is extremely rare, and no prior reports describe the concurrent and persistent onset of all three symptoms, underscoring the need for enhanced toxicity monitoring and patient education.
Related
- Hypomagnesemia in Hypoparathyroidism, Sensorineural Deafness, and Renal Dysplasia Syndrome Caused by Pathogenic Variants of GATA3
- Clinical and radiographic improvement in suspected pulmonary lymphangitic carcinomatosis-associated hypoxemic respiratory failure following iruplinalkib-based treatment in ALK-positive lung adenocarcinoma after sequential treatment with ensartinib and lorlatinib: a two-patient case report
- Lorlatinib in frontline treatment of advanced ALK-positive non-small cell lung cancer: a highly efficient new standard of care but still challenging to manage
- Miliary Brain Metastasis with Perivascular Enhancement in ALK-Positive Lung Cancer: A Rapid Recovery after Concurrent Lorlatinib and Whole-brain Radiotherapy
- Expert recommendations on the management of major and minor toxicities associated with the use of lorlatinib in Latin America
BibTeX
@article{cai2026lorlatinibassociated,
title = {{Lorlatinib-associated sensorineural deafness in a non-small cell lung cancer patient with ALK-fusion: a Case Report}},
author = {Lijuan Cai and Wenying Peng and Runxiang Yang and Jiao Wu and Chunxiang Luo and Fang Yang},
journal = {Frontiers in Pharmacology},
year = {2026},
month = nov,
doi = {10.3389/fphar.2026.1969621},
url = {https://www.frontiersin.org/articles/10.3389/fphar.2026.1969621},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Lorlatinib-associated sensorineural deafness in a non-small cell lung cancer patient with ALK-fusion: a Case Report
AU - Lijuan Cai
AU - Wenying Peng
AU - Runxiang Yang
AU - Jiao Wu
AU - Chunxiang Luo
AU - Fang Yang
PY - 2026
DA - 2026/11/02
JO - Frontiers in Pharmacology
DO - 10.3389/fphar.2026.1969621
UR - https://www.frontiersin.org/articles/10.3389/fphar.2026.1969621
AB - In the era of precision targeted therapy, anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) have significantly improved survival outcomes for patients with ALK-positive non-small cell lung cancer (NSCLC). The third-generation ALK inhibitor lorlatinib, characterized by superior antitumor activity, a broader spectrum of ALK mutation sites and enhanced central nervous system (CNS) penetrability, has yielded breakthrough clinical benefits. However, lorlatinib has a distinct adverse event profile, with edema, dyslipidemia, central and peripheral nervous system toxicities, posing key clinical management challenges. Herein, we report the first case of an ALK-fusion NSCLC patient who developed peripheral neuropathy, dysarthria, and sensorineural deafness following lorlatinib treatment. While dysarthria and peripheral neuropathy have been previously documented, sensorineural deafness is extremely rare, and no prior reports describe the concurrent and persistent onset of all three symptoms, underscoring the need for enhanced toxicity monitoring and patient education.
SN - 1663-9812
ER -